4th Annual Genome Editing USA Congress

350+ end users representing internationally renowned research And academic institutions.

Tue, Apr 07 – 08, 2020   |   12:00 h
Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, Massachusetts 02111, United States

3 outstanding programmes bringing together Europe's key genomics experts in Next Generation Sequencing, Single Cell Analysis, Genome Editing.

80+ case studies, solution And technology presentations And 2 interactive workshops over the 2 days.

07 April 2019 - Day One
- Genome Editing Technologies And Techniques
- Drug Discovery And Development Applications in In Vivo Therapeutics

08 April 2019 - Day Two
- Drug Discovery And Development - Target Identification and Validation
- Non-Human Models in Diagnostics And Therapeutics

View Agenda: http://bit.ly/2rLMzeL

2020 Live Webinar
Chemically-Modified Polynucleotides for Inhibiting, Expressing and Repairing Nucleic Acids: Then And Now
Presented by Tod Woolf, Founder And CEO, ETAGEN Pharma, Inc.
Tuesday, 10 March 2020 | 03:30 PM GMT
Register: https://bit.ly/2QvO7Us

Twitter: https://go.evvnt.com/554687-2?pid=5731
LinkedIn: https://go.evvnt.com/554687-3?pid=5731

General Admission: USD 299.0

Speakers: George Church, Professor of Genetics, Health Sciences and Technology, Wyss Institute at Harvard University, Tod Woolf, Founder and Chief Executive Officer, ETAGEN Pharma, Inc., Svetlana Belyanskaya, Scientific Leader, Encoded Library Technologies, GlaxoSmithKline, Salil Desai, Chief Executive Officer, PhenomYX, Luhan Yang, Co-Founder and Chief Scientific Officer, eGenesis, Nadeem Sarwar, Founder And President, Eisai Center for Genetics Guided Dementia Discovery, Eisai, John Reidhaar-Olson, Senior Director, Pfizer, Oleg Iartchouk, Director, Genomics and Next-Generation Sequencing, Novartis

Hosted by
Oxford Global